Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: CHOCOlate MeLatonin for AdolescenT MigrainE [Phase 2]
Phase 2 trial update for CHOCOlate MeLatonin in adolescents with migraine has completed with posted results.
-
FDA approval · 2021-06-03FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)
The FDA approved Eli Lilly's supplemental application for Reyvow (lasmiditan).
-
FDA approval · 2021-05-27FDA Approved: NURTEC ODT — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for NURTEC ODT (rimegepant sulfate) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2021-05-19FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Amitriptyline hydrochloride as an original-application generic from Unichem Pharmaceuticals (USA), Inc. (ANDA 214548).
-
FDA label_change · 2021-05-11FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for Aimovig (erenumab-aooe) by Amgen.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine [Phase 2]
A Phase 2 trial update evaluating lasmiditan (LY573144) for a single migraine attack in Japanese participants with migraine has completed wi…
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: Vagus Nerve Stimulation: Treatment for Gulf Veterans With Gulf War Illness [NA]
Clinical trial on vagus nerve stimulation for Gulf War Illness has completed; results posted in 2021.
-
FDA approval · 2021-04-28FDA Approved: TREXIMET — Supplemental Application (Currax Pharmaceuticals LLC)
The FDA approved a supplemental application for TREXIMET (sumatriptan succinate and naproxen sodium) from Currax Pharmaceuticals LLC. This a…
-
FDA approval · 2021-04-26FDA Approved: DICLOFENAC POTASSIUM — Supplemental Application (Trifluent Pharma LLC)
FDA approved a supplemental application for Diclofenac potassium from Trifluent Pharma LLC as a generic product.
-
FDA approval · 2021-04-23FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for divalproex sodium from Aurobindo Pharma Limited, a generic formulation.
-
FDA approval · 2021-04-23FDA Approved: NARATRIPTAN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Naratriptan filed by Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2021-04-14Clinical Trial Update: Decoding Pain Sensitivity in Migraine With Multimodal Brainstem-based Neurosignature [Phase 4]
Phase 4 clinical trial update exploring pain sensitivity in migraine using multimodal brainstem-based neurosignature.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean [Phase 3]
Phase 3 trial comparing lasmiditan to placebo for acute treatment of migraine in Korean population has completed.
-
FDA approval · 2021-03-31FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Diclofenac Sodium from Actavis Pharma, Inc. under ANDA074514. The approval covers an updated for…
-
CLINICAL_TRIALS trial_result · 2021-03-30Clinical Trial Update: A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine [Phase 2]
Phase 2 study evaluating the efficacy and safety of oral LAT8881 in acute migraine has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-30Clinical Trial Update: An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) [Phase 2]
Phase 2 trial results for DFN-02 (sumatriptan nasal spray 10 mg) assessing efficacy and safety in migraine headaches; completed with results…
-
FDA approval · 2021-03-23FDA Approved: IMITREX — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for IMITREX (sumatriptan) submitted by GlaxoSmithKline LLC. The approval updates the product labelin…
-
FDA approval · 2021-03-23FDA Approved: IMITREX — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for IMITREX (sumatriptan) submitted by GlaxoSmithKline LLC.
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine [Phase 1]
Phase 1 trial updating safety, tolerability, and drug–drug interaction of ubrogepant with erenumab or galcanezumab in migraine patients; res…
-
FDA approval · 2021-03-04FDA Approved: BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE PHOSPHATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for the analgesic combination butalbital/acetaminophen/caffeine/codeine phosphate from Actavis Pharm…
-
CLINICAL_TRIALS trial_result · 2021-03-04Clinical Trial Update: A Controlled Trial of Erenumab in Migraine Prevention [Phase 3]
Phase 3 trial results for erenumab in migraine prevention have completed with results posted.
-
FDA approval · 2021-03-03FDA Approved: UBRELVY — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for UBRELVY (ubrogepant) from Allergan, Inc., resulting in updated labeling for the drug.
-
CLINICAL_TRIALS trial_result · 2021-02-25Clinical Trial Update: Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents [NA]
Clinical trial update on Nerivio for acute treatment of migraine in adolescents; study terminated with posted results.
-
FDA approval · 2021-02-23FDA Approved: MIGRAINE RELIEF — Original Application (CHAIN DRUG MARKETING ASSOCIATION, INC.)
FDA approved Migraine Relief as an original ANDA for a combination analgesic containing acetaminophen, aspirin, and caffeine. The product is…
-
FDA approval · 2021-02-22FDA Approved: SUMATRIPTAN — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s generic Sumatriptan under an Original Application (ANDA) for the treatment of acute migraine. This marks the a…